{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-034698","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2026-08-27T20:15:47+00:00","discovered_at":"2026-08-27T20:17:16.022439+00:00","generated_at":"2026-08-27T20:17:22.800990+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned","bullets":["Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.","Merger completed Aug 27, 2026; Forte is now a wholly owned subsidiary of argenx BV.","Total consideration ~$2.2B funded from argenx cash; covers options, RSUs, warrants.","All prior directors/officers replaced; new board includes Arjen Lemmen, Karl Gubitz, Malini Moorthy.","Company requested Nasdaq delisting and will file Form 15 to suspend SEC reporting."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-034698","json":"https://secwatch.observer/filing/0001140361-26-034698.json","markdown":"https://secwatch.observer/filing/0001140361-26-034698.md","text":"https://secwatch.observer/filing/0001140361-26-034698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/0001140361-26-034698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/ef20081182_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-27T20:17:22.800990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}